Figure 5
From: Development of Small Molecule MEIS Inhibitors that modulate HSC activity
Human bone marrow hematopoietic cell expansion post MEISi treatments. (A) the percentage of CD34+ hBM MNC content, (B) the percentage of CD133+ hBM MNC content, (C) the percentage of CD90+hBM MNC content D) the percentage of CD34+CD38− hBM MNC content, (E) the percentage of CD34+CD133+CD90+ hBM MNC content, (F) the percentage of CD34+CD133+CD90+CD38− hBM MNC post 7 days of treatment with MEISi-1 and MEISi-2 compared to the cells treated with DMSO. n = 3, *p < 0.05.
